Collegium Pharmaceutical (NASDAQ:COLL) Price Target Cut to $46.00 by Analysts at Needham & Company LLC

Collegium Pharmaceutical (NASDAQ:COLL) had its price objective dropped by research analysts at Needham & Company LLC from $56.00 to $46.00 in a report issued on Thursday,Benzinga reports. The firm presently has a “buy” rating on the specialty pharmaceutical company’s stock. Needham & Company LLC’s price target suggests a potential upside of 58.59% from the company’s previous close.

A number of other brokerages have also issued reports on COLL. Zacks Research lowered shares of Collegium Pharmaceutical from a “strong-buy” rating to a “hold” rating in a report on Tuesday, July 28th. Truist Financial upgraded shares of Collegium Pharmaceutical to a “strong-buy” rating in a report on Monday, June 15th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Collegium Pharmaceutical in a research note on Monday, July 6th. Finally, Wall Street Zen cut shares of Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a research report on Saturday, July 25th. One investment analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and two have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, Collegium Pharmaceutical has an average rating of “Moderate Buy” and a consensus price target of $55.00.

Collegium Pharmaceutical Stock Performance

NASDAQ COLL traded down $6.74 on Thursday, reaching $29.00. 1,366,140 shares of the stock were exchanged, compared to its average volume of 474,402. The company has a current ratio of 1.71, a quick ratio of 1.62 and a debt-to-equity ratio of 2.47. Collegium Pharmaceutical has a one year low of $29.21 and a one year high of $50.79. The firm has a market capitalization of $940.75 million, a PE ratio of 14.28 and a beta of 0.73. The company’s 50-day simple moving average is $34.95 and its two-hundred day simple moving average is $37.24.

Collegium Pharmaceutical (NASDAQ:COLL) last announced its quarterly earnings data on Thursday, August 6th. The specialty pharmaceutical company reported $1.92 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.72 by $0.20. Collegium Pharmaceutical had a net margin of 9.41% and a return on equity of 95.18%. The firm had revenue of $199.88 million during the quarter, compared to analysts’ expectations of $199.62 million. During the same period in the prior year, the company posted $1.68 earnings per share. The company’s revenue for the quarter was up 6.3% compared to the same quarter last year. Analysts expect that Collegium Pharmaceutical will post 6.76 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the company. Group One Trading LLC acquired a new stake in shares of Collegium Pharmaceutical during the fourth quarter worth about $28,000. Caitong International Asset Management Co. Ltd boosted its position in Collegium Pharmaceutical by 205.3% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 635 shares of the specialty pharmaceutical company’s stock worth $29,000 after purchasing an additional 427 shares in the last quarter. PNC Financial Services Group Inc. increased its position in shares of Collegium Pharmaceutical by 42.2% in the first quarter. PNC Financial Services Group Inc. now owns 1,408 shares of the specialty pharmaceutical company’s stock valued at $47,000 after buying an additional 418 shares in the last quarter. Kemnay Advisory Services Inc. acquired a new position in shares of Collegium Pharmaceutical during the 4th quarter worth approximately $61,000. Finally, Mirae Asset Global Investments Co. Ltd. lifted its position in shares of Collegium Pharmaceutical by 26.1% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,536 shares of the specialty pharmaceutical company’s stock valued at $71,000 after buying an additional 318 shares in the last quarter.

Collegium Pharmaceutical News Roundup

Here are the key news stories impacting Collegium Pharmaceutical this week:

• Positive Sentiment: Q2 adjusted earnings exceeded expectations. Collegium reported adjusted EPS of $1.92, ahead of the $1.72 consensus estimate and up from $1.68 a year earlier. Revenue of $199.9 million also modestly surpassed estimates and increased approximately 6% year over year. Collegium Pharmaceutical Beats Q2 Earnings and Revenue Estimates
• Positive Sentiment: ADHD growth and the AZSTARYS acquisition support the long-term outlook. JORNAY PM revenue rose 41% to $46.1 million, while AZSTARYS contributed $12.9 million during its partial quarter following the completed acquisition. Collegium raised its 2026 AZSTARYS revenue outlook to $65 million–$75 million from $60 million–$70 million. Collegium Reports Q2 Results and Completes AZSTARYS Acquisition
• Positive Sentiment: Operating cash flow was strong at $71.3 million, and adjusted EBITDA increased 8% year over year to $113.8 million, providing financial support for integration and future investment.
• Neutral Sentiment: The company reaffirmed its JORNAY PM revenue forecast of $190 million–$200 million, indicating continued confidence in its established ADHD product.
• Negative Sentiment: Full-year guidance was cut below Wall Street expectations. Collegium now expects 2026 product revenue of $825 million–$855 million, down from $865 million–$895 million and below the approximately $872.4 million consensus estimate. Adjusted EBITDA guidance was also reduced to $445 million–$470 million from $475 million–$500 million.
• Negative Sentiment: The pain portfolio remains under pressure. Pain revenue declined 9% year over year to $140.9 million, led by a 24% drop in Nucynta franchise revenue and a 14% decrease in Xtampza ER revenue. Management attributed the guidance reduction largely to lower-than-expected pricing for Nucynta authorized generics.
• Negative Sentiment: GAAP results deteriorated to a $15.1 million net loss from $12.0 million of net income a year earlier, while GAAP operating expenses increased 45%, partly reflecting acquisition-related costs and higher amortization.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company focused on the development, manufacture and commercialization of products for pain management and opioid dependence. The company’s core expertise lies in its DETERx microsphere technology, a platform designed to provide extended-release delivery of active pharmaceutical ingredients while deterring manipulation for unintended routes of abuse.

The company’s principal marketed products include Xtampza® ER (extended-release oxycodone), which received approval from the U.S.